Jeffery L. Kutok
Geen lopende functies
Loopbaan van Jeffery L. Kutok
Eerdere bekende functies van Jeffery L. Kutok
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| EPIZYME, INC. | Chief Tech/Sci/R&D Officer | 23-03-2020 | 01-09-2022 |
| INFINITY PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01-01-2010 | 31-03-2020 |
The Brigham & Women's Hospital, Inc.
 The Brigham & Women's Hospital, Inc. Hospital/Nursing ManagementHealth Services The Brigham & Women's Hospital, Inc. provides health care services. The firm offers treatment for cancer, cardio vascular, neurosciences, orthopedic, arthritis, women's health and clinical services. The company was founded in 1980 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01-01-2002 | 01-12-2010 |
| Harvard Medical School | Corporate Officer/Principal | 01-01-2002 | 01-12-2010 |
Opleiding van Jeffery L. Kutok
| Stony Brook University | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 6 |
Operationeel
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
Sectoraal
| Consumer Services | 3 |
| Health Technology | 3 |
| Health Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| INFINITY PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
The Brigham & Women's Hospital, Inc.
The Brigham & Women's Hospital, Inc. Hospital/Nursing ManagementHealth Services The Brigham & Women's Hospital, Inc. provides health care services. The firm offers treatment for cancer, cardio vascular, neurosciences, orthopedic, arthritis, women's health and clinical services. The company was founded in 1980 and is headquartered in Boston, MA. | Health Services |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
- Beurs
- Insiders
- Jeffery L. Kutok
- Ervaring
